Agree with all the above comments. The potential is huge. I wonder what data FDA saw to grant the FTD.
Recently I glanced back to the Ann’s dating till 2017 when the company’s target was MS and that failed and the company had a different name. While not dwelling on it I decided to focus on the present. Let’s hope this incarnation and this drug + disease target will help us get across the line.
Ann: FDA Fast Track Designation for Narmafotinib, page-6
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.5¢ |
Change
-0.005(3.13%) |
Mkt cap ! $42.59M | |||
| Open | High | Low | Value | Volume |
| 16.0¢ | 16.0¢ | 15.5¢ | $8.402K | 52.79K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 97806 | 15.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 374091 | 4 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| ATX (ASX) Chart |